# A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

> **NCT07058012** · PHASE2 · RECRUITING · sponsor: **NSABP Foundation Inc** · enrollment: 79 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** cemiplimab plus fianlimab
- **DRUG:** cemiplimab + REGN7075
- **OTHER:** ctDNA testing

## Key facts

- **NCT ID:** NCT07058012
- **Lead sponsor:** NSABP Foundation Inc
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-17
- **Primary completion:** 2029-04-17
- **Final completion:** 2029-06-01
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07058012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07058012, "A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07058012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*